GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 7,286 | 8,968 | 9,682 | 39,505 | 27,555 |
| Marketable Securities | 19,454 | 23,011 | 26,031 | N/A | N/A |
| TOTAL | $27,193 | $32,169 | $35,798 | $39,567 | $27,643 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 246 | 0 | 0 | 0 | 0 |
| TOTAL | $246 | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $27,439 | $32,169 | $35,798 | $39,567 | $27,643 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 8,113 | 8,189 | 2,802 | 1,497 | 2,377 |
| Accrued Expenses | 1,170 | 1,901 | 749 | 906 | 856 |
| Other current liabilities | 120 | 138 | 340 | 842 | 362 |
| TOTAL | $9,503 | $10,259 | $3,922 | $3,276 | $3,626 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 147 | 0 | 0 | 0 | 0 |
| TOTAL | $147 | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $9,650 | $10,259 | $3,922 | $3,276 | $3,626 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,016 | 1,070 | 1,018 | 1,015 | 704 |
| Common Shares | 32 | 1,145 | 3,446 | 10,744 | 25,977 |
| Retained earnings | -659,024 | -653,584 | -635,393 | -629,940 | -625,079 |
| Other shareholders' equity | 1 | 1 | -168 | -168 | -168 |
| TOTAL | $17,789 | $21,910 | $31,876 | $36,291 | $24,017 |
| Total Liabilities And Equity | $27,439 | $32,169 | $35,798 | $39,567 | $27,643 |